Struggling U.S. Biotech Sold To South Korean Corporation
This article was originally published in PharmAsia News
Executive Summary
Once a burgeoning biotech success story with its discovery of the HIV fusion-inhibitor class of drugs, including its own Fuzeon treatment, Trimeris will be merged into a South Korean medical equipment company, Arigene, if a proposed $81 million sale goes through